- Home
- MNOV vs HLP Comparison
MNOV vs HLP Comparison
Compare MNOV & HLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | HLP |
|---|---|---|
| Founded | 2000 | 2021 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 76.4M |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MNOV | HLP |
|---|---|---|
| Price | $1.42 | $0.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | 21.8K | ★ 190.2K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,360,807.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $180.00 | N/A |
| P/E Ratio | ★ N/A | $51.63 |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.17 | $0.61 |
| 52 Week High | $1.96 | $1.72 |
Technical Indicators
Market Signals| Indicator | MNOV | HLP |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 45.29 |
| Support Level | $1.40 | $0.85 |
| Resistance Level | $1.43 | $1.14 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 37.71 | 25.03 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.